Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05385757
Other study ID # 258638
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 22, 2020
Est. completion date December 2024

Study information

Verified date June 2023
Source Institute of Child Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Childhood uveitis (inflammation inside the eye) is an uncommon disorder that carries the risk of blindness. Inadequate treatment of active inflammation has been shown to be related to a poor outcome. There has been no population-based, prospective longitudinal study of all-cause childhood uveitis, with resultant limitations in the evidence base used to counsel affected families, balance treatment decisions, or plan further research. The aim of the study is to describe the characteristics of childhood-onset uveitis and describe outcomes. The investigators shall also aim to identify the socio-demographic, clinical, biological and treatment-related determinants of outcome. Early (1-2 years following diagnosis) outcomes will be described in the first instance: However, through the creation of a national inception cohort, the investigators shall enable longer-term studies of outcome for affected children and families. There will be no change to routine clinical care.


Description:

Background: Childhood uveitis descriptive term for a group of rare inflammatory eye disease, which are typically chronic, relapsing-remitting in nature, and of uncertain aetiology (idiopathic). Visual loss occurs due to structural damage caused by uncontrolled inflammation. Understanding of the determinants of long-term outcome is limited, particularly the predictors of therapeutic response or how to define disease control. Aims: To describe disease natural history and outcomes amongst a nationally representative group of children with non-infectious uveitis, describe the impact of disease course on quality of life for both child and family, and identify determinants of adverse visual, structural and developmental outcomes. Methods: UNICORNS is a prospective longitudinal multicentre cohort study of children newly diagnosed with uveitis about whom a core minimum clinical dataset will be collected. Participants and their families will also complete patient-reported outcome measures (PROMS) at study entry and annually from recruitment. PROMS collected at baseline are: - Strength and Difficulties Questionnaire (SDQ): this is to screen the emotional and behavioural aspects of the participants' lives - Child Health Utility 9D (CHU9D): generic preference based measure of health related quality of life - Children's Sleep Habits Questionnaire (CHSQ): this evaluates incidence of behaviours linked with typical paediatric sleep difficulties - 100-mm General Evaluation (GE): visual analogue score 100mm long used to capture overall perception of the burden of disease PROMS collected at year 1 and annually (subject to investigations of instrument redundancy) are: - Child Health Utility 9D (CHU9D): generic preference based measure of health related quality of life - 100-mm General Evaluation (GE): visual analogue score 100mm long used to capture overall perception of the burden of disease - Paediatric Quality of life Score (PedsQL): a brief questionnaire used to evaluate health related quality of life in children - Vision related quality of life metric - Children and Young People (VQoL_CYP): these instruments captures the functional and broader impacts of living with a visual disability The association of patient (child- and treatment- dependent) characteristics with outcome will be investigated using logistic and ordinal regression models which incorporate adjustment for within-child correspondence between eyes for those with bilateral disease and repeated outcomes measurement. Discussion: Through this population based, prospective longitudinal study of childhood uveitis, the investigators will describe the characteristics of childhood onset disease. Early (1-2 years following diagnosis) outcomes will be described in the first instance, and through the creation of a national inception cohort, longer term studies of outcome for affected children and families will be enabled.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 250
Est. completion date December 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Children newly diagnosed with uveitis (within previous 6 months) - Age < 18years Exclusion Criteria: - Uveitis due to malignancy - Uveitis due to ocular trauma (including iatrogenic, ie intraocular surgery) - Uveitis due to confirmed ocular infection - Children with developmental disorders or impairments which prevent their self-report of their function level or quality of life

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Belfast Royal Victoria Hospital NHS Foundation Trust Belfast
United Kingdom Birmingham Women's and Children's Hospital NHS Foundation Trust Birmingham
United Kingdom Royal Bournemouth Christchurch Hospitals NHS Foundation Trust Bournemouth
United Kingdom Bradford Teaching Hospitals NHS Foundation Trust Bradford
United Kingdom University Hospitals Bristol NHS Foundation Trust Bristol
United Kingdom Cambridge University Hospital NHS Foundation Trust Cambridge
United Kingdom Cardiff and Vale University Health Board Hospitals Cardiff
United Kingdom Mid Essex Hospital Trust Chelmsford
United Kingdom Ninewells Hospital Dundee
United Kingdom Princess Alexandra Eye Pavilion Edinburgh
United Kingdom Royal Children's Hospital Glasgow
United Kingdom James Paget University Hospitals NHS Foundation Trust Great Yarmouth
United Kingdom Hull University Teaching Hospitals NHS Trust Hull
United Kingdom Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom Alder Hey Hospital NHS Foundation Trust Liverpool
United Kingdom Great Ormond Street Hospital NHS Foundation Trust London
United Kingdom Moorfields Eye Hospital NHS Foundation Trust London
United Kingdom Royal Free London NHS Foundation Trust London
United Kingdom St Thomas' Hospital London
United Kingdom Maidstone and Tunbridge Wells NHS Trust Maidstone
United Kingdom Manchester University NHS Foundation Trust Manchester
United Kingdom Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle
United Kingdom Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich
United Kingdom Nottingham University Hospitals NHS Trust Nottingham
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford
United Kingdom Sussex Eye Hospital and Royal Alexandra Children's Hospital Redhill
United Kingdom Sheffield Children's Hospitals NHS Foundation Trust Sheffield
United Kingdom University Hospital Southampton NHS Foundation Trust Southampton
United Kingdom Southend University Hospital NHS Foundation Trust Westcliff-on-Sea
United Kingdom Royal London Hospital Whitechapel
United Kingdom York Teaching Hospital NHS Foundation Trust York

Sponsors (2)

Lead Sponsor Collaborator
Institute of Child Health National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Kellett S, Rahi JS, Dick AD et al. UNICORNS: Uveitis in childhood prospective national cohort study protocol [version 1; peer review: awaiting peer review]. F1000Research 2020, 9:1196 (https://doi.org/10.12688/f1000research.26689.1)

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of ocular complications New incident of sight threatening ocular complications, including glaucoma, cataract and macular oedema Up to 3 years
Primary Pediatric Quality of Life Inventory Score Quality of life (patient reported outcomes) using Pediatric Quality of Life Inventory (PedsQL) in which items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life) Up to 3 years
Secondary Corticosteroid exposure Total prescribed topical and systemic corticosteroid burden Up to 3 years
Secondary Attainment of disease control Number of children achieving absolute control defined as absence of inflammation Relative control defined as the absence of inflammation greater than 0.5 The lowest grade of inflammation, with the use of less than one drop of topical corticosteroid Up to 3 years
Secondary Health Utility Child Health Utility Metric (CHU9D), with scores ranging from 0.33 (worst health state) to 1.00 (best health state) Up to 3 years
Secondary Change in Pediatric Quality of Life Inventory Score Change in child reported quality of life using Pediatric Quality of Life Inventory (PedsQL) in which items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life), and a change of greater than 5 is clinically meaningful Over one year from baseline to year one
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT06260449 - Different Treatment Approaches of Presumed Trematode-Induced Uveitis N/A

External Links